ENZN — Enzon Pharmaceuticals Cashflow Statement
0.000.00%
- $2.97m
- -$40.29m
- $0.03m
Annual cashflow statement for Enzon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.31 | -0.469 | -0.186 | 1.37 | 0.778 |
| Deferred Taxes | |||||
| Changes in Working Capital | 0.931 | -0.032 | -0.271 | 0.089 | 0.002 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -0.38 | -0.501 | -0.659 | 1.3 | 1.12 |
| Financing Cash Flow Items | -0.524 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 43.1 | 0 | — | -1.27 | -1.27 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 42.7 | -0.501 | -0.659 | 0.03 | -0.153 |